REV-ERB raises a handful of sensible questions. This page answers them in order, starting with the fundamentals and moving to applications.
This page was last updated on 2025-08-15 and is reviewed periodically as new material appears.
SR9009 stability depends on temperature, moisture, light, and solvent. Solid material is generally kept cool and dry, while solutions may require protection from repeated warming and cooling. Degradation can appear as color changes, precipitate, or new chromatographic peaks. Researchers should follow supplier instructions and their own stability data. Long-term storage conditions for human use have not been established because the compound lacks approved clinical formulation.
SR9009 is supplied as a solid research chemical, often in milligram quantities. Laboratories typically weigh it in a controlled environment because fine powders can disperse. Stock solutions are commonly prepared in dimethyl sulfoxide and stored in small aliquots to reduce freeze-thaw cycles. Personal protective equipment and chemical fume hoods are standard when handling unknown or potent compounds. These practices address laboratory safety rather than human use.
Regulatory status varies by country and intended use. Major drug agencies have not granted marketing authorization for SR9009 as a medicine, and it is not listed as a controlled substance in many jurisdictions. It is often sold as a research chemical, a category that may fall outside pharmaceutical manufacturing rules. Buyers should verify local laws and supplier documentation, including certificates of analysis. The lack of standardized quality controls raises concerns about identity, purity, and actual content in products marketed online.
In laboratory settings, SR9009 is commonly identified by its molecular structure and its interaction with REV-ERB receptors. Vendors may list it under synonyms such as Stenabolic or REV-ERB agonist, but those names do not define purity or identity. Analytical confirmation typically uses high-performance liquid chromatography with ultraviolet detection or liquid chromatography–mass spectrometry. A reference standard is needed to compare retention time and mass spectrum, because the compound can be confused with related research chemicals.
| Property | Value | Notes |
|---|---|---|
| Synonyms | SR9009; Stenabolic | Stenabolic is an informal name |
| Common form | Crystalline powder | Supplied in milligram to gram quantities |
| Long-term storage | -20 °C, desiccated, protected from light | Reduces degradation |
| Detection technique | LC-MS/MS | Common in anti-doping and research analysis |
| Regulatory status | Prohibited in sport by WADA | Not approved for human therapeutic use |
Laboratory studies often administer SR9009 by injection because oral absorption appears poor in rodents. Reported pharmacokinetic properties include rapid metabolism and low systemic exposure after oral dosing. Human pharmacokinetic data are sparse, so absorption, distribution, metabolism, and excretion in people are not well defined. Some research explores related REV-ERB compounds with improved drug-like properties. Regulatory approval for any REV-ERB agonist as a human medicine has not been granted to date.
SR9009 is a synthetic small molecule studied as an agonist of the nuclear receptors REV-ERBα and REV-ERBβ, also called NR1D1 and NR1D2. These receptors help regulate circadian rhythms and metabolic gene programs. The compound was developed for laboratory research, not as an approved therapeutic. Its identity is distinct from steroid hormones and selective androgen receptor modulators. Scientific interest centers on how REV-ERB activation changes gene expression in cells and animal models.
At the molecular level, SR9009 binds the ligand-binding domain of REV-ERB and strengthens recruitment of corepressor proteins such as NCoR and HDAC3. This increases repression of target genes, including Bmal1 and other clock-controlled and metabolic genes. In rodent studies, such changes have been linked to altered lipid handling, glucose metabolism, and energy expenditure. The precise chain of events between receptor binding and whole-body effects remains an active area of research. Findings in animals do not automatically translate to humans.
Storage recommendations for SR9009 reference material typically specify a freezer at -20 °C or lower, with protection from moisture and light. Repeated freeze-thaw cycles can degrade small molecules and introduce variability. Stock solutions in dimethyl sulfoxide are often aliquoted to avoid repeated handling. Stability studies may examine degradation under heat, humidity, and light exposure. The compound's thiophene and nitro groups can participate in reactions that alter analytical signals over time, so such changes affect quantitative results.
Quality control for research materials includes identity confirmation by nuclear magnetic resonance and purity assessment by high-performance liquid chromatography. Mass spectrometry provides molecular weight confirmation and can detect related impurities. Purchasers should request a certificate of analysis that lists lot-specific data. Online products advertised for human use often lack such documentation. Distinguishing legitimate research material from mislabeled or contaminated samples is a recurring challenge in independent testing, and independent laboratories may use orthogonal methods to verify identity.
Detection of SR9009 in biological samples usually relies on liquid chromatography coupled to tandem mass spectrometry. This approach separates the compound from matrix components and identifies it by mass transitions. Because SR9009 can undergo metabolism, laboratories often look for both parent drug and specific metabolites. Sample preparation may involve protein precipitation or solid-phase extraction. Method validation examines sensitivity, carryover, and interference from related substances, and reference standards are required for accurate calibration.
Because REV-ERB receptors are core clock components, SR9009 has been examined for effects on daily rhythms as well as metabolism. Research has explored whether the compound can shift or reinforce circadian gene expression in tissues such as liver and muscle. Some studies report improved metabolic markers in obese or diabetic mice, while others show context-dependent responses. Questions remain about which effects are direct, which are secondary to timing, and how they might differ across species.
SR9009 is a synthetic small molecule studied as an agonist of REV-ERB nuclear receptors. REV-ERB alpha and REV-ERB beta help regulate circadian rhythms and metabolic gene expression. In laboratory research, SR9009 has been used to probe how these receptors affect skeletal muscle, liver, and adipose tissue. The compound was identified in academic drug-discovery work and is often described in scientific literature by its chemical name and research code. It is not an approved medicine, and human clinical data remain limited or absent.
The mechanism of action involves binding to REV-ERB receptors and recruiting corepressor complexes, which represses target gene transcription. This contrasts with many nuclear receptor agonists that activate transcription. Downstream effects may include changes in autophagy, mitochondrial biogenesis, and lipid handling, but the precise pathways remain an active area of study. Whether these molecular events translate into meaningful physiological effects in humans is unresolved. Most evidence comes from cultured cells and rodent models rather than human participants.
SR9009 is a synthetic small molecule developed as an agonist of the nuclear receptors REV-ERBα (NR1D1) and REV-ERBβ (NR1D2). These receptors help regulate circadian rhythms and metabolic gene expression. In cell and animal studies, SR9009 alters transcription of genes involved in lipid metabolism, inflammation, and mitochondrial function. It is not an approved medicine, and its pharmacological profile in humans remains largely uncharacterized. The compound is frequently discussed in the context of circadian biology and metabolic research rather than clinical use.
The first Masons in Cuba were most likely Speculative and Operative, not Symbolic, and arrived by the early half of the 18th Century, as indicated by archaeological evidences of Masonic symbols that were found carved into the stones of the Convent of San Francisco as Mason's marks, which have been relatively dated to its current construction beginning in 1716, the year before Symbolic Freemasonry was established in England. These symbols were carved by operative stonemasons who had been brought into the country by the Catholic Church from disparate parts of the European continent to work on the construction project. At that time, Operative Masonic and Speculative Masonic guilds in Spain were not centralized, functioning instead as independent and unique Lodges, and it was not until 1728 that they formed the unified body of Freemasonry in Spain. The Convent of San Francisco did also receive renovations in 1731, but Havana's official City Historian, Eusebio Leal Spengler, stated during an inspection of the site that the marks were part of the construction of the convent and were not added anytime after the first half of the 18th Century. In 1738, ten years after Symbolic Freemasonry arrived in Spain, Pope Clement XII issued a Papal bull banning the practice of Freemasonry in the Catholic church. Following this, the Grand Inquisitor of Spain issued an edict banning the practice within the Spanish church by punishment of excommunication and a fine. In 1750, José Torrubia, while working for the Holy Office of the Inquisition in Madrid, went undercover as a Freemason in Spain.
=== Dressings === After a wound is irrigated, debrided, and, if possible, closed, it should be dressed appropriately. The goals of a wound dressing are to act as a barrier to the outside environment, facilitate wound healing, promote hemostasis, and act as a form of mechanical debridement during dressing changes. The ideal wound dressing maintains a moist environment to optimize wound healing but is also capable of absorbing excess fluid as to avoid skin maceration or bacterial growth. Several wound dressing options are available, each tailored to different kinds of wounds:
== Etymology == The name Qingzhou, meaning "Light Boat", is derived from a famous poem by the Tang dynasty poet Li Bai: "The light boat has already passed ten thousand mountains" (轻舟已过万重山). According to the developers, the name symbolizes the spirit of overcoming difficulties and the determination to explore the stars.
=== Politics === DiCaprio endorsed Democratic candidate Hillary Clinton for the 2016 United States presidential election. In March 2020, DiCaprio attended a fundraiser for Joe Biden at the home of Paramount Pictures executive Sherry Lansing. Prior to the 2020 election, DiCaprio narrated a Netflix documentary series about voting rights, stating, "All of us may have been created equal. But we'll never actually be equal until we all vote. So don't wait." On social media, DiCaprio urged voters to make a plan to cast their ballots and to draw attention to voter suppression and restrictive voter ID laws, citing VoteRiders as a source of information and assistance. In 2023, DiCaprio testified during the trial against Prakazrel Michel, who is being accused of participating in a foreign influence campaign that was aimed at the Obama and Trump administrations. In 2024, DiCaprio formally endorsed Kamala Harris for president due to her policies on climate change mitigation, and criticized her Republican opponent Donald Trump.
A good practice is a procedure or set of procedures that are prescribed or accepted as being suitable or effective within a given professional or commercial setting. They are used in quality guidelines and regulations, including the pharmaceutical and food industries, for example good agricultural practice (GAP) (see more examples below). In general, GxP is a placeholder abbreviation for the good practice within a particular field or fields, where the "x" can be substituted for the field(s) in question. GxP can also be used to refer to collections of quality guidelines. To denote the current good practice, a "c" or "C" is sometimes added to the front of the initialism (cGxP), which may hint that any good practice may be subject to future change. For example, "current good manufacturing practice" may be abbreviated "cGMP".
Sources: en.wikipedia.org
=== Cyclization of amino acids === Lactams can be formed from cyclisation of amino acids via the coupling between an amine and a carboxylic acid within the same molecule. Lactamization is most efficient in this way if the product is a γ-lactam. For example, Fmoc-Dab(Mtt)-OH, although its side-chain amine is sterically protected by extremely bulky 4-Methyltrityl (Mtt) group, the amine can still intramolecularly couple with the carboxylic acid to form a γ-lactam. This reaction almost finished within 5 minutes with many coupling reagents (e.g. HATU and PyAOP).
=== Protocol example === A ZooMS protocol (Fig. 1) typically consists of an extraction, denaturation, digestion and filtration step, followed by mass spectrometric analysis. Various destructive and non-destructive extraction protocols have already been discussed in some detail above. The key is to extract the protein preserved in the sample and then bring it into solution, usually an ammonium bicarbonate buffer. Denaturation is done to unfold the proteins and make them more accessible for the enzymatic digestion. It is done by heating the solubilised sample at around 65 °C. Then an enzyme, trypsin, is added to the solution. Trypsin cleaves the protein after every arginine or lysine amino acid in its sequence, resulting in peptide fragments of predictable masses. After digestion the sample is filtered with C18 filters to get rid of non-proteinaceous material and the sample is now ready for mass spectrometric analysis, which for ZooMS generally means MALDI-TOF MS.
It has been indicated that where there was a policy of providing IAP for GBS colonized mothers, the overall risk of EOGBS is 0.3%. Though maternal GBS colonization is the key determinant for EOD, other factors also increase the risk. These factors include onset of labor before 37 weeks of gestation (premature birth), prolonged rupture of membranes (> 18 h before delivery), intra-partum fever (>38 °C, >100.4 °F), amniotic infections (chorioamnionitis), young maternal age, and low levels of GBS anticapsular polysaccharide antibodies in the mother. Nevertheless, most babies who develop EOD are born to GBS colonized mothers without any additional risk factor. A previous sibling with EOD is also an important risk factor for the development of the infection in subsequent deliveries, probably reflecting a lack of GBS polysaccharides protective antibodies in the mother. Heavy GBS vaginal colonization is also associated with a higher risk for EOD. Overall, the case–fatality rates from EOD have declined, from 50% observed in studies from the 1970s to 2 to 10% in recent years, mainly as a consequence of improvements in therapy and management. Fatal neonatal infections by GBS are more frequent among premature infants. GBS LOD affects infants from 7 days to 3 months of age and is more likely to cause bacteremia or meningitis. LOD can be acquired from the mother or from environmental sources. Hearing loss and mental impairment can be long-term sequelae of GBS meningitis.
During the events of the crossover film Tokusou Sentai Dekaranger vs. Abaranger, Trinoid #0 Saunaginnan resurrects Ben G, who is subsequently killed by Deka Master, Pink, and Break, as well as Abare Killer. Ben G is voiced by Nobuyuki Hiyama (檜山 修之, Hiyama Nobuyuki). Cristonian Ferley (クリスト星人ファーリー, Kurisuto Seijin Fārī): A werewolf/vampire bat–themed criminal from Planet Cristo who is charged with burglary and murdering several S.P.D. officers. As his body is photosensitive, he tasks a Batsuroid with piloting a Kaijuki called Devil Capture 4 (デビルキャプチャー4, Debiru Kyapuchā Fō) to distract the Dekarangers while Ferley locates and eats a mineral called Lunar Metal so he can roam freely in daylight. Devil Capture 4 is destroyed by Dekaranger Robo while Ferley is deleted by the Dekarangers via the D-Bazooka. In the direct-to-video special Tokusou Sentai Dekaranger Super Video: Super Finisher Match! Deka Red vs. Deka Break, a variation of Ferley called Burning Ferley (バーニング・ファーリー, Bāningu Fārī) appears as part of a simulation training session. Ferley is voiced by Hisao Egawa (江川 央生, Egawa Hisao). Titarnian Metiussl (ティタン星人メテウス, Titan Seijin Meteusu): A brutal flame/astronaut–themed criminal and self-proclaimed "Destroyer King" (破壊王, Hakaiō) from Planet Titarn who seeks out an android girl named Flora, whom he created to control his giant creation Machine Monster Gigas (マシンモンスター・ギーガス, Mashin Monsutā Gīgasu). He tasks a Batsuroid with piloting a gladiator-themed Kaijuki called Cannon Gladiator (キャノングラディエーター, Kyanon Guradiētā) and attacking the Deka Base while he locates Flora.
The escalation of American threats against Greenland has been linked by several commentators to the apparent success of the 2026 United States intervention in Venezuela. Some commentators have also linked the Greenland Crisis to Trump's threats against Canada. Former Premier of Ontario and Permanent Representative of Canada to the United Nations Bob Rae stated that Trump "doesn't take Canada's sovereignty seriously", while former Principal Secretary to the Prime Minister Gerald Butts stated that, although he didn't believe Trump would invade Canada directly, "we're going to see a lot of threats, and we're going to see a lot of seeding of pro-American activity by the Americans in Canadian life". NBC News reported in mid-January 2026 that, according to senior American officials, Trump was "privately ramping up his focus on another target in the Western Hemisphere, increasingly complaining to aides in recent weeks about Canada's vulnerability to US adversaries in the Arctic". Trump's aggressive negotiation tactics have prompted comparisons with the madman theory. James D.
Sources: en.wikipedia.org
Laboratories commonly use liquid chromatography coupled with mass spectrometry to detect SR9009. The method can identify the compound and estimate concentration in a sample. Detection limits depend on the matrix and instrument.
Research-grade purity indicates a supplier's measured percentage of the intended compound. It does not guarantee safety, sterility, or suitability for human consumption. Buyers should request a certificate of analysis with chromatograms and test methods.
Sports regulators prohibit SR9009 because it is a non-approved substance with potential performance-altering effects. Its presence can be detected in anti-doping testing. Athletes are responsible for substances found in their samples.
Liquid chromatography–mass spectrometry is common for identity and purity checks. High-performance liquid chromatography with ultraviolet detection can also be used. Both methods require a suitable reference standard.